Counsel patients regarding the potential risk for MTC with the use of RYBELSUS or OZEMPIC tablets and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness)
100 percent subcutaneous | | Reported weight data | 12.4 % (36 mg, 72 wk, ATTAIN-1) | 24.2 % (12 mg, 48 wk, Phase 2) | | Food restriction | None | Not applicable | | Status | FDA-approved (Foundayo, April 2026) | Research substance, not approved | The table illustrates that the higher weight values of retatrutide result from a broader receptor activation and the injection-driven complete entry of the active substance, while orforglipron has its strength in ease of administration and oral availability
Published data suggests ipamorelin may increase IGF-1 levels by 15-30% in responder populations, while sermorelin studies report variable outcomes ranging from modest to moderate GH elevation depending on dosing, frequency, and baseline age
Because many people access these medications through online platforms or busy primary care offices, patients often miss out on the counseling that helps manage side effects and support long-term results, says Joni Rampolla, RDN, a dietitian specializing in weight health and metabolic wellness and the founder of Nutrition Coaching 4U
